HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-21-2014, 10:14 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Raloxifene and the Prevention of Osteoporosis

Slide 25

Raloxifene and the Prevention of Osteoporosis

Next Section >
One SERM that may exhibit some of these properties is raloxifene (Evista®), a drug approved by the FDA in 1997 for preventing osteoporosis in postmenopausal women.
Raloxifene appears to function like estrogen in bone, acting to maintain bone strength and increase bone density. In addition, raloxifene also resembles estrogen in its ability to lower LDL cholesterol levels, thereby decreasing the risk of heart disease.
Although information on the long-term risks and benefits of raloxifene is limited compared to tamoxifen, preliminary evidence suggests that raloxifene may exert these beneficial effects on bones, heart, and blood vessels without increasing a woman’s risk of developing cancer.
'lizbeth is offline   Reply With Quote
Old 05-21-2014, 10:15 AM   #2
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: Raloxifene and the Prevention of Osteoporosis

Slide 26

Raloxifene and Risk of Invasive Breast Cancer

In animal studies, raloxifene (Evista®) reduced the incidence of both breast and uterine cancer. And in preliminary human trials, raloxifene reduced the risk of breast cancer without the unwanted stimulation of uterine cell division that is exhibited by tamoxifen (Nolvadex®). As a result of these findings, the National Cancer Institute sponsored a human clinical study to directly compare the effects of tamoxifen and raloxifene in postmenopausal women at higher than average risk for this disease. The trial, named STAR (Study of Tamoxifen and Raloxifene), was begun in 1999 and is following more than 19,000 women for a period of 5 to 10 years.
Early STAR trial results show that raloxifene works as well as tamoxifen in reducing risk by about 50 percent for invasive breast cancer in postmenopausal women. And raloxifene has fewer side effects. Participants in STAR who were assigned to take raloxifene had 36 percent fewer uterine cancers and 29 percent fewer blood clots from that drug than did the women assigned to take tamoxifen.
On the other hand, tamoxifen reduces the incidence of lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) by half, while raloxifene did not have an effect on these diagnoses. (LCIS and DCIS are sometimes called noninvasive or stage 0 breast cancers.)
A woman can go to http://www.cancer.gov/bcrisktool/ to determine if her individual risk for invasive breast cancer is above average.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 04:28 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter